TIVC Form 4: Sheryle Bolton receives 12,500 stock options, vesting quarterly
Rhea-AI Filing Summary
Sheryle Bolton, a director of Tivic Health Systems, Inc. (TIVC), was granted a stock option on 08/06/2025 to purchase 12,500 shares of common stock at an exercise price of $3.32 per share. The option is held directly and covers 12,500 underlying shares. The option expires on 08/05/2035.
The grant vests in four equal quarterly installments (rounded down) measured from the grant date, with 100% vesting upon the first anniversary of the grant. The form was signed by an attorney-in-fact on behalf of the reporting person.
Positive
- Director Sheryle Bolton received a clear, time-based equity award: 12,500 stock options with explicit quarterly vesting and full vesting after one year
- Long-term alignment: Option expiration in 2035 provides a multi-year incentive horizon
Negative
- None.
Insights
TL;DR: Routine director equity award; grants management alignment but no evidence here of material dilution or extraordinary terms.
The filing documents a standard director equity grant: a stock option for 12,500 shares at an exercise price of $3.32, exercisable under a vesting schedule of four equal quarterly installments and fully vested after one year. The option is direct and expires on 08/05/2035. From a governance perspective, the disclosure is complete on grant mechanics and vesting. The filing does not provide information on total outstanding shares, prior holdings, or option plan limits, so materiality relative to shareholder dilution cannot be assessed from this form alone.
TL;DR: Compensation details are clear: 12,500 options at $3.32 with time-based quarter vesting and a 10-year term; appears routine.
The derivative reported is a stock option to purchase 12,500 shares with an exercise price of $3.32 and an expiration date of 08/05/2035. The vesting triggers are time-based: four equal quarterly installments culminating in full vesting at one year. The form confirms direct ownership of the option post-grant. Absent additional pay-rate, grant-date valuation, or company-wide compensation context, this grant reads as a typical long-term incentive for a director rather than an extraordinary compensation event.